A randomized phase 2 trial assessed the combination of the CTLA-4 inhibitor ipilimumab with the PD-1 inhibitor nivolumab compared to nivolumab alone in recurrent ovarian cancer. The gene discussed is PDCD1; the disease is ovarian carcinoma.